NCT05949008View on ClinicalTrials.gov

Effect of Metformin, a Drug Used to Treat Diabetes, vs Placebo

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

November 22, 2023

Primary Completion Date

July 30, 2027

Study Completion Date

July 30, 2027

Conditions
NIDDMObesity
Interventions
DRUG

Metformin Extended Release (ER) Oral Tablet

Metformin ER will be provided as 1000 mg capsules by Qingdao Baheal Pharmaceutical Co., Ltd. In addition to the active ingredient metformin HCl,each tablet contains the following inactive ingredients: Povidone, Sodium Lauryl Sulfate, Magnesium Stearate, Cellulose Acetate, Polyethylene Glycol (PEG 400, PEG 8000), Triacetin, Hypromellose, Titanium Dioxide, Polysorbate 80, Ferrosoferric Oxide, Shellac.

DRUG

Placebo

Matching placebo will be provided as 1000 mg capsules

Trial Locations (1)

90024

UCLA Center for Human Nutrition, Los Angeles

All Listed Sponsors
lead

University of California, Los Angeles

OTHER

NCT05949008 - Effect of Metformin, a Drug Used to Treat Diabetes, vs Placebo | Biotech Hunter | Biotech Hunter